Stockreport

Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meetin...

Akari Therapeutics Plc - American Depositary Shares  (AKTX) 
US:NASDAQ Investor Relations: investor.akaritx.com/investor-relations
PDF Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatri [Read more]